Sorafenib in Recurrent and/or Metastatic Salivary Gland Carcinomas: Phase II Study
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Objective response
Response Rate according to RECIST criteria. Response will be evaluated every 2 months.
8 weeks
No
Comitato Etico Indipendente:Fondazione IRCCS Istituto Nazionale Tumori
INT29/10
NCT01703455
September 2010
January 2013
Name | Location |
---|